Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Ratings
Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
10d ago
ATOS
Premium
The Fly
Atossa Therapeutics reports results from Phase 2 EOP sub-study
10d ago
ATOS
Premium
Ratings
Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position
11d ago
ATOS
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
22d ago
ATOS
CYCC
Premium
The Fly
Atossa Therapeutics announces issuance of U.S. patent for (Z)-endoxifen
24d ago
ATOS
Premium
The Fly
Atossa Therapeutics proposes study aimed at reducing interval breast cancer
25d ago
ATOS
Premium
The Fly
Atossa Therapeutics announces issuance of U.S. patent
1M ago
ATOS
Premium
The Fly
Atossa Therapeutics and Nona Biosciences partner in breast cancer antibodies
1M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress
2M ago
ATOS
Premium
Ratings
Strategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics
2M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Reports 2024 Financial Results and Updates
2M ago
ATOS
Premium
The Fly
Atossa Therapeutics reports Q4 EPS (20c), consensus (22c)
2M ago
ATOS
Premium
Ratings
Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating
2M ago
ATOS
Premium
Pre-Earnings
ATOS Earnings this Week: How Will it Perform?
2M ago
ATOS
Premium
Ratings
Positive Buy Rating for Atossa Therapeutics Driven by Promising Z-endoxifen Efficacy in Breast Cancer
2M ago
ATOS
Premium
The Fly
Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen
2M ago
ATOS
Premium
The Fly
Atossa Therapeutics issues statement in response to PTAB ruling
4M ago
ATOS
Premium
The Fly
Atossa Therapeutics issues letter to shareholders
4M ago
ATOS
Premium
The Fly
Atossa Therapeutics ‘applauds’ Surgeon General’s advisory on alcohol
5M ago
ATOS
Premium
The Fly
Atossa Therapeutics to present poster on Z-endoxifen at SABCS
5M ago
ATOS
Premium
The Fly
Atossa Therapeutics announces full result from KARISMA-Endoxifen trial
5M ago
ATOS
Premium
The Fly
Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study
5M ago
ATOS
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
